Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for COO and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for COO and 80,000+ other tickers.
See exactly how COO's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for COO and 80,000+ other tickers.
The Cooper Companies, Inc. (COO) operates as a global medical device firm, primarily focused on developing, producing, and distributing products through two distinct business units: CooperVision and CooperSurgical. CooperVision specializes in contact lenses. Their product range includes spherical lenses for common vision issues like nearsightedness and farsightedness, as well as advanced lenses such as toric for astigmatism, multifocal for presbyopia, and specialized options addressing myopia, dry eyes, and eye fatigue. These vision correction solutions are available across the Americas…
New York, New York--(Newsfile Corp. - October 23, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of The Cooper Companies, Inc. (NASDAQ: COO) resulting from allegations that CooperCompanies may have issued materially misleading business information to the investing public. SO WHAT: If you purchased CooperCompanies securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
NEW YORK, Oct. 22, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of The Cooper Companies, Inc. (NASDAQ: COO) resulting from allegations that Cooper Companies may have issued materially misleading business information to the investing public.
NEW YORK, Oct. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of The Cooper Companies, Inc. ("Cooper" or the "Company") (NASDAQ: COO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
New York, New York--(Newsfile Corp. - October 21, 2026) - WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of The Cooper Companies, Inc. (NASDAQ: COO) resulting from allegations that CooperCompanies may have issued materially misleading business information to the investing public. SO WHAT: If you purchased CooperCompanies securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
NEW YORK, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of The Cooper Companies, Inc. (“Cooper” or the “Company”) (NASDAQ: COO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.